Sabine Tejpar

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status

Eric Van Cutsem, Claus-Henning Köhne, István Láng et al. · Journal of Clinical Oncology · 2011 · 1.9K citations · Full text

Medicine, Oncology, Pharmacology +17

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer

Sabine Tejpar, Sebastian Stintzing, Fortunato Ciardiello et al. · JAMA Oncology · 2016 · 722 citations · Full text

Medicine, Cancer Biology, Oncology +17

KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

Eric Van Cutsem, István Láng, G D’Haens et al. · Journal of Clinical Oncology · 2008 · 373 citations

Medicine, Oncology, Pharmacology +15

Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia

Wouter M. Tiel Groenestege, Stéphanie Thebault, Jenny van der Wijst et al. · Journal of Clinical Investigation · 2007 · 359 citations · Full text

Medicine, Nephrology, Oncology +16

Association of <i>KRAS</i> G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab

Sabine Tejpar, Ilhan Celik, Michael Schlichting et al. · Journal of Clinical Oncology · 2012 · 353 citations

Medicine, Oncology, Pharmacology +16